secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001493152-24-051209
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics secures up to $25M standby equity facility with Yorkville; first $5M funded
--------------------------------------------------------------------------------

- Yorkville advanced $5M initial tranche of $15M pre-paid convertible notes; two additional $5M tranches subject to conditions.
- Conversion price lower of $2.41/share or 94% of 5-day VWAP; 0% interest (18% upon default), matures Dec 2025.
- Additional $10M common stock purchase commitment available under SEPA over two years, subject to Yorkville's consent.
- CEO states proceeds will fund first-in-human diabetic foot ulcer trial and psoriasis IND-enabling studies.
- Shareholder approval required for issuances exceeding 19.99% of outstanding shares (Exchange Cap).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224051209/0001493152-24-051209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224051209/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-051209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer